1. Articles in category: News

    1-24 of 227 1 2 3 4 5 6 7 8 9 10 »
    1. Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.

      Oncol Rep. 2018 Feb 09;:

      Authors: Li C, Yang C, Wei G

      Abstract Resistance is the major cause of cisplatin treatment failure in neuroblastoma (NB). Vandetanib is widely used in the treatment of several cancers. In the present study, we aimed to determine the potential of vandetanib in cisplatin‑resistant NB therapy.

      Read Full Article
      Mentions: Treatment
    2. Estrogen causes neuroblastoma cells to mature into neurons

      The female sex hormone estrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers demonstrate that estrogen treatment and overexpression of the estrogen receptor cause malignant neuroblastoma cells to mature into neuron-like cells. The studygives hope of new treatment possibilities.

      Read Full Article
      Mentions: Treatment
    3. Oestrogen causes neuroblastoma cells to mature into neurons

      Oestrogen causes neuroblastoma cells to mature into neurons

      ( Karolinska Institutet ) The female sex hormone oestrogen can perform an important role in neuroblastoma, a form of cancer mainly affecting young children. In laboratory experiments, researchers at Karolinska Institutet in Sweden demonstrate that oestrogen treatment and overexpression of the oestrogen receptor cause malignant neuroblastoma cells to mature into neuron-like cells. The study, which is published in PNAS, gives hope of new treatment possibilities.

      Read Full Article
      Mentions: Treatment MYCN
    4. Fertility preservation options in pediatric and adolescent patients with cancer.

      Fertility preservation options in pediatric and adolescent patients with cancer.

      Cancer. 2018 Jan 25;:

      Authors: Burns KC, Hoefgen H, Strine A, Dasgupta R

      Abstract The incidence of childhood cancer has steadily increased since the 1950s, with approximately 16,000 children diagnosed each year. However, with the advent of more effective multimodal therapies, childhood cancer survival rates have continued to improve over the past 40 years, with >80% of patients now surviving into adulthood.

      Read Full Article
    5. 'Hijacker' drives cancer in some patients with high-risk neuroblastoma

      Researchers have identified mechanisms that drive about 10 percent of high-risk neuroblastoma cases and have used a new approach to show how the cancer genome “hijacks” DNA that regulates other genes. The resulting insights may help scientists develop more effective therapies, including ...

      Read Full Article
    6. Microbiome predicts blood infections in pediatric cancer patients

      Microbiome predicts blood infections in pediatric cancer patients

      Cancer patients receive essential medicines, fluids, blood and nutrients through long, flexible tubes called central venous catheters, or central lines. But every year in the United States, these central lines are associated with an estimated 400,000 blood infections, many of which are fatal, and which cost the healthcare system upwards of $18 billion dollars annually. But what if some or even many of these infections aren't, in fact, introduced by central lines?

      Read Full Article
    7. The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      The novel kinase inhibitor ponatinib is an effective anti-angiogenic agent against neuroblastoma.

      Invest New Drugs. 2016 Dec;34(6):685-692

      Authors: Whittle SB, Patel K, Zhang L, Woodfield SE, Du M, Smith V, Zage PE

      Abstract Background High-risk neuroblastoma has poor outcomes with high rates of relapse despite aggressive treatment, and novel therapies are needed to improve these outcomes.

      Read Full Article
      Mentions: Treatment Relapse
    8. Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras.

      Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras.

      Cancer Immunol Immunother. 2018 Jan 03;:

      Authors: Dierckx de Casterlé I, Fevery S, Rutgeerts O, Poosti F, Struyf S, Lenaerts C, Waer M, Billiau AD, Sprangers B

      Read Full Article
      Mentions: Bone Marrow GvHD
    9. mTHPC- conjugated Gold Nanoparticles as a Tool to Improve Photodynamic Therapy.

      mTHPC- conjugated Gold Nanoparticles as a Tool to Improve Photodynamic Therapy.

      ACS Appl Mater Interfaces. 2018 Jan 03;:

      Authors: Haimov E, Weitman H, Polani S, Schori H, Zitoun D, Shefi O

      Abstract Photodynamic Therapy (PDT) is a promising therapeutic modality for cancer. However, current protocols using bare drugs suffer from several limitations that impede its beneficial clinical effects. Here, we introduce a new approach for an efficient PDT treatment.

      Read Full Article
    10. Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Thousands of children with cancer across Europe could miss out on the latest targeted treatments because of delays reforming outdated regulations, leading cancer research institutions, charities and expert bodies are warning.

      The European Commission has...

      Read Full Article
    11. Late effects of treatment in survivors of childhood cancers: A single-centre experience.

      Late effects of treatment in survivors of childhood cancers: A single-centre experience.

      Indian J Med Res. 2017 Aug;146(2):216-223

      Authors: Seth R, Singh A, Seth S, Sapra S

      Abstract BACKGROUND & OBJECTIVES: With improved survival of childhood cancer patients, the number of long-term cancer survivors is increasing. Some studies have assessed the long-term morbidity after childhood cancer treatment in the developing countries.

      Read Full Article
    12. Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Delay in reforming European rules could deny thousands of children access to latest cancer drugs

      Thousands of children with cancer across Europe could miss out on the latest targeted treatments because of delays reforming outdated regulations, leading cancer research institutions, charities and expert bodies are warning.

      Read Full Article
    13. Dinutuximab for the treatment of pediatric patients with neuroblastoma.

      Dinutuximab for the treatment of pediatric patients with neuroblastoma.

      Drugs Today (Barc). 2017 Sep;53(9):469-476

      Authors: Greenwood K, Foster JH

      Abstract Dinutuximab is a monoclonal antibody targeted at disialoganglioside (GD2), a tumor-associated antigen widely expressed in human neuroblastoma cells. The incorporation of dinutuximab into standard treatment regimens for patients with high-risk neuroblastoma has changed the landscape of neuroblastoma therapy.

      Read Full Article
      Mentions: Antibody Treatment
    14. Low-Dose Treatment with Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease

      Low-Dose Treatment with Interleukin-2 Across Multiple Studies Shows Benefits in Chronic Graft-Versus-Host Disease

      Daily low doses of the immune signaling protein interleukin-2 (IL-2) can safely benefit patients who develop chronic graft-versus-host disease following stem cell transplants, including particular benefit in pediatric patients in one small study, report scientists from Dana-Farber Cancer Institute.

      Read Full Article
      Mentions: Treatment GvHD
    15. Immunotherapy Drug for Rheumatoid Arthritis Nearly Eliminates Severe Acute Graft-Versus-Host Disease after Hematopoietic Stem Cell Transplant

      Results from a phase 2 clinical trial, presented by Seattle Children's Research Institute at the 59th American Society of Hematology (ASH) Annual Meeting, show that the drug Abatacept (Orencia) nearly eliminated life-threatening severe acute graft-versus-host disease (GvHD) in patients receiving hematopoietic stem cell transplants.

      Read Full Article
    16. Researchers identify an indirect way of countering a key genetic lesion in neuroblastoma

      Researchers identify an indirect way of countering a key genetic lesion in neuroblastoma

      Pediatric cancers tend to have relatively "quiet" genomes compared to tumors in adults. They harbor fewer discrete genetic mutations, especially in genes for readily "druggable" targets (such as protein kinases). Instead, these tumors tend to feature other kinds of genetic alterations, such as duplications or translocations.

      Read Full Article
      Mentions: MYCN
    17. Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy.

      Excellent prognosis of patients with intermediate-risk neuroblastoma and residual tumor postchemotherapy.

      J Pediatr Surg. 2017 Nov 09;:

      Authors: Amano H, Uchida H, Tanaka Y, Tainaka T, Mori M, Oguma E, Kishimoto H, Kawashima H, Arakawa Y, Hanada R, Koh K

      Read Full Article
    18. St. Baldrick's Foundation Appoints Neuroblastoma Expert, Dr. Susan Cohn, to its Board of Directors

      St. Baldrick's Foundation Appoints Neuroblastoma Expert, Dr. Susan Cohn, to its Board of Directors

      LOS ANGELES, Dec. 4, 2017 /PRNewswire-USNewswire/ -- The St. Baldrick's Foundation, the largest private funder of childhood cancer research grants, is proud to announce Dr. Susan Cohn, M.D., dean for Clinical Research at the University of Chicago Medicine & Biological Sciences, professor of pediatrics and section chief Hematology/Oncology in the Department of Pediatrics, as the newest member of its board of directors.

      Read Full Article
    19. New developments in immunotherapy for pediatric solid tumors.

      New developments in immunotherapy for pediatric solid tumors.

      Curr Opin Pediatr. 2017 Nov 20;:

      Authors: Schultz LM, Majzner R, Davis KL, Mackall C

      Abstract PURPOSE OF REVIEW: Building upon preclinical advances, we are uncovering immunotherapy strategies that are translating into improved outcomes in tumor subsets. Advanced pediatric solid tumors carry poor prognoses and resultant robust efforts to apply immunotherapy advances to pediatric solid tumors are in progress.

      Read Full Article
      Mentions: Immunotherapy
    20. Neural crest derived progenitor cells contribute to tumor stroma and aggressiveness in stage 4/M neuroblastoma.

      Neural crest derived progenitor cells contribute to tumor stroma and aggressiveness in stage 4/M neuroblastoma.

      Oncotarget. 2017 Oct 27;8(52):89775-89792

      Authors: Linares-Clemente P, Aguilar-Morante D, Rodríguez-Prieto I, Ramírez G, de Torres C, Santamaría V, Pascual-Vaca D, Colmenero-Repiso A, Vega FM, Mora J, Cabello R, Márquez C, Rivas E, Pardal R

      Read Full Article
    21. Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma.

      Vascularized Tissue-Engineered Model for Studying Drug Resistance in Neuroblastoma.

      Theranostics. 2017;7(17):4099-4117

      Authors: Villasante A, Sakaguchi K, Kim J, Cheung NK, Nakayama M, Parsa H, Okano T, Shimizu T, Vunjak-Novakovic G

      Abstract Neuroblastoma is a vascularized pediatric tumor derived from neural crest stem cells that displays vasculogenic mimicry and can express a number of stemness markers, such as SOX2 and NANOG.

      Read Full Article
      Mentions: Treatment
    1-24 of 227 1 2 3 4 5 6 7 8 9 10 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (2 articles) MYCN
  4. General Informations in the News

    1. (4 articles) Treatment
  5. Treatments in the News

    1. (1 articles) Surgery